Healius (ASX:HLS) has agreed to sell Agilex Biolabs to Novotech in a AU$150 million deal, according to a Thursday report by the Australian Financial Review, citing people with knowledge of the deal.

The report said Healius finalised terms with Novotech's owners on Thursday, with a disclosure detailing the deal expected imminently.

Novotech is a clinical research organization valued at more than $3 billion and controlled by global buyout firm TPG alongside Singaporean investors GIC and Temasek, per the report.

Healius did not immediately respond to MT Newswires request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)